Background: Compared with angiogenesis, arteriogenesis is a distinct process based on the remodeling and maturation of pre-existing arterioles into large conductance arteries. Therapeutic angiogenesis has been proposed as a potential treatment for ischemic atherosclerotic diseases. Since a variety of angiogenic factors have been tested with inconsistent so far clinical results, the challenge remains in identifying the factor(s) that will stimulate functional neovascularization. Thrombin has been reported to play a pivotal role in the initiation of angiogenesis by regulating and organizing a network of angiogenic mediators. Also, it was recently demonstrated that thrombin is a potent anti-apoptotic factor for endothelial cells, providing evidence on a potential role of thrombin in vascular protection and maintenance of vessel integrity. Based on these observations, we hypothesized that thrombin may promote the development of mature functional blood vessels. 
In clinical practice, some patients with peripheral vascular disease present few or no symptoms despite a significant stenosis or even occlusion of a main feeding artery. This is mostly evident in patients with slowly progressing vascular occlusions, where an endogenous collateral circulation had sufficient time to develop, bypassing the site of stenosis and protecting the downstream tissue from ischemic injury. On the other hand, in most cases the vascular lesion progresses too fast or the collateral circulation develops too slowly and remains insufficient to compensate for the obstructed artery. In these cases, therapeutic stimulation and acceleration of this natural protective mechanism has the potential to become an alternative approach to improve blood supply to compromised tissue. Indeed, many pharmacologic approaches were used to stimulate the growth of collateral arteries based mainly on the knowledge gained from studying pathologic angiogenesis. 1 A variety of protein-, gene-, and cell-based cytokines and angiogenic growth factors have been investigated in vitro and in vivo. 2, 3 However, the hypoxia-driven sprouting of capillaries observed in pathologic angiogenesis is fundamentally different from the beneficial arteriogenesis (the enlargement of small pre-existing anastomoses towards large conductance arteries) in arterial occlusive diseases. 4 This difference is likely the explanation of the limited success of first clinical trials and warrants further investigation of the mechanisms that regulate the arteriogenic process.
Thrombin, apart from its central role in blood coagulation, exerts a wide range of effects on endothelial cells, which may contribute to the control of many functions, including vascular tone, hemostasis, inflammation, and angiogenesis. 5 Thrombin, mainly through proteinaseactivated receptor 1 (PAR1) signalling, stimulates many vascular cells as well as endothelial cells and regulates the release, expression, and activation of the majority of angiogenesis mediators. 6 For example, thrombin-induced angiogenesis in the chick embryo system 7 was associated with upregulation of vascular endothelial growth factor (VEGF) as well as angiopoietin-2 (Ang-2). 8 In line with this, thrombin upregulated VEGF 9 and Ang-2 10 in endothelial cells. Another important effect of thrombin was the potentiation of mitogenic activity of VEGF on endothelial cells. 11 In addition, thrombin plays a role in promoting angiogenesis by PAR1-independent mechanisms. It has been demonstrated that immobilized thrombin functioning directly through its RGD sequence interacted with ␣␤3 and ␣5␤1 integrins and promoted attachment, migration, and survival of endothelial cells. 12, 13 These effects of thrombin provide a plausible explanation for the angiogenesis par excellence occurring within thrombi, where thrombin is trapped, in several pathophysiologic conditions. Furthermore, it was recently shown that soluble thrombin protected endothelial cells from apoptosis via two mechanisms: a minor contribution was mediated by PAR1 activation and a major contribution by interaction with ␣␤3 and ␣5␤1 integrins in which the catalytic site of thrombin is not necessary. 14 The involvement of thrombin in endothelial cell survival may open new insights on the role of thrombin in vascular protection and provides evidence for an essential contribution of thrombin in the establishment and maintenance of vessel wall integrity.
Interplay between pro-angiogenic growth factors and vascular protection mechanisms are essential for the cascade of reactions involved in blood vessel formation and maturation. In this context, the thrombin-mediated arterial protection together with its potent angiogenic ability may prove to be useful in the development and maturation of new large conductance collateral vessels that may compensate for atherosclerotic arterial occlusions and achieve effective reperfusion of distal ischemic tissue. 15, 16 We hypothesized that thrombin stimulates arteriogenesis and enhances hemodynamic recovery of experimental limb ischemia. We investigated the arteriogenic properties of thrombin in a rabbit hindlimb ischemia model after bilateral femoral artery excision, where the formation of functional collateral vessels with vascular stability is essential for the recovery of ischemic tissues. We have shown that a single administration of thrombin was able of establishing functional vascular networks.
MATERIAL AND METHODS
The study included 74 (n ϭ 74) New Zealand White rabbits (male sex, approximately 6-month-old, weight 3.0-4.0 kgs) that underwent bilateral femoral artery surgical excision. On the 20th postsurgical day increasing doses of thrombin or VEGF or bFGF were injected in one ischemic limb per rabbit and an equal volume of normal saline to the contralateral control limbs; ie, groups of ischemic controls. A group of nonoperated subjects (n ϭ 6) were also included in the study and served as an external control group of normal rabbit hindlimbs; ie, group of normal controls (Fig 1) .
Animal hindlimb ischemia model and experimental protocol. The in vivo investigation protocol conformed to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication No. 85-23, revised 1996) and was approved by local University Hospital's local Scientific and Ethical Committee. Bilateral hindlimb ischemia was surgically induced in all rabbits under dissociative anesthesia with an intramuscular injection of ketamine 50 mg/kg and xylazine 10 mg/kg as described elsewhere. 17 Briefly, animals were placed on a heating pad and an intravenous normal saline drip (15 mL/h) was administered through a Flowchart of experimental protocol. Seventy-four (n ϭ 74) New Zealand White rabbits underwent bilateral femoral artery surgical excision. On the 20th postsurgical day increasing doses of thrombin or VEGF or bFGF were injected in one ischemic limb per rabbit and an equal volume of normal saline to the contralateral control limbs; ie, groups of ischemic controls. A group of nonoperated subjects (n ϭ 6) was included in the study as an external control group of normal rabbit hindlimbs; ie, group of normal controls. On the 40th postsurgical day imaging and histology was performed as indicated.
marginal auricular vein. After sterile surgical draping, hindlimbs were longitudinally incised on the medial thighs. Incisions extended from the inguinal ligament to just proximal to the patella. The femoral artery and all its major branches, including the inferior epigastric, deep femoral, lateral circumflex, and superficial epigastric artery, were dissected (Fig 2, A and B) . The distal external iliac artery and the aforementioned major branches were ligated. Experienced veterinary staff closely monitored all rabbits during the immediate postoperative period.
Escalating doses of vascular endothelial growth factor (1 g or 3 g or 10 g VEGF; Chemicon International Inc, Temecula, Calif) or basic fibroblast growth factor (1 g or 3 g or 10 g bFGF, Chemicon International Inc) or bovine thrombin (500 IU or 1500 IU or 5000 IU or 15,000 IU Thrombin-JMI, King Pharmaceuticals, Inc, Middleton, Wis) were intramuscularly injected in one ischemic limb per rabbit, randomly selecting between left and right (Table) . The growth factors were diluted in 1mL of solution and administered with three separate injections (0.33 mL per injection, injection points approximately 1.5 cm apart) along the course of the excised femoral artery and medially to the bone. An equal volume of normal saline (1mL) was injected in the same way in the contralateral limb in order to serve as an internal control for each study group. Injections were performed on the 20th postsurgical day. The 20-day interval between the surgical excision of the femoral artery and the injection of the agents was chosen with respect to quiescence of the endogenous angiogenesis, which is believed to occur 10 to 20 days after the induction of acute limb ischemia in the rabbit model. 15, 17 It has been shown that although ischemiadriven capillary sprouting is maximized within 5 days of femoral artery removal, angiographic collateralization and improvement of reserve blood flow capacity reach a plateau after 20 days. 15 All animal subjects were then followed up with morphological and functional in vivo imaging 20 days after the delivery of the angiogenic stimulant, ie, on the 40th postsurgical day, so as to allow for an equal time interval for the development and augmentation of new collateral arteries. The group of normal controls underwent only the imaging modalities (Fig 1) .
Transauricular intra-arterial digital subtraction angiography and computerized image postprocessing. Digital subtraction angiography (DSA) was performed in the medial thigh of both ischemic hindlimbs in order to depict the newly developed collateral vessels and obtain an accurate quantitative score of the arteriogenic outcome triggered by the administration of the indicated substances. [18] [19] [20] Intra-arterial vascular access was established in all rabbits through a minimally invasive transauricular route, which obviates major surgery and minimizes subjects' stress and pain, as recently described. 21 Briefly, a 0.018-inch hydrophilic guidewire (V18, Boston Scientific, Natick, Mass) was advanced in the central auricular artery under fluoroscopic navigation and a 4F vascular sheath was inserted in the common carotid artery after serial dilations of the auricular subcutaneous tract. The rabbit infrarenal abdominal aorta was selectively catheterized with a straight 4F catheter by routine endovascular instruments and maneuvers under fluoroscopic guidance. The tip of the 4F angiographic catheter was located above the iliac bifurcation in order to simultaneously record DSA images of both hindlimbs, avoid variations of the animal's blood pressure and heart rate, or arterial spasm that could affect DSA acquisition and eliminate movement artefacts when comparing with the control limbs. DSA images were obtained with the clinical Philips DVI-S angiography unit using the acquisition protocol of 1 image per second at 40 -90 KV. Nonionic iodinated contrast (Iomeron, 400 mg iodine per mL, Bracco, Milan, Italy) was infused at a rate of 1 mL/s (5 mL total contrast volume) with an automated angiographic injector pump. The hindlimbs of the rabbits were positioned 25 cm below the X-ray tube and the focal spot to intensifier distance was 110 cm. In order to achieve field homogenization and increase image quality, an aluminium filter was interposed between the subject and the intensifier.
For postprocessing of DSA images (Fig 2, A and B ), we applied a recently described method for quantitative analysis of the collateral vessels in angiography images, based on the concept of multiscale structural tensor. 22 Briefly, the baseline digital angiographic image is initially smoothed by a 2D Gaussian sigma standard deviation. Consequently, the Hessian matrix, also called structural matrix, is produced by the second order Gaussian derivatives of the image. A step-wise multiscale eigen-value analysis of the Hessian matrix achieves accurate extraction and segmentation of the vasculature map within the image. A region-of-interest (ROI) was drawn in the area of the medial thigh to include the newly developed collaterals (Fig 2, B) . The same ROIs that were used in all limbs in order to reproduce equal sampling areas and pixel counts were further normalized against a known standard size (tip of the 4F angiographic catheter that was positioned in the distal abdominal aorta and included in the DSA frames; 1F ϭ 333 m). The selected vascular objects were initially measured for their total vessel area and then for their length, using a skeletonization procedure that collapses vessel diameter to one pixel. Focusing on the process of arteriogenesis and collateralization, the software segmented and quantified collateral vessels with a diameter greater than 500 m. The applied software may be found as a free download at http://stat.med.upatras.gr/JDI.
Functional evaluation with dynamic computed tomography. In order to noninvasively evaluate the hemodynamic properties of the evolving revascularization process and the newly developed arterial networks, we used the dynamic computed tomography (CT) technology. [23] [24] [25] We performed a first-pass study at the level of the saphenous artery, 2 cm below the knee joint and distal to the area of the injected angiogenic factors. On the 40th postsurgical day anesthetized subjects were placed in the supine position in a clinical new-generation 16-row CT modality (Lightspeed, GE Medical Systems, Milwaukee, Wis). An initial scan (scout) of the animals was undertaken to allow localization of the knee articulations, which served as the corre- sponding bone landmarks for the popliteal and saphenous arteries. Iodinated contrast (Iomeron, 400 mg iodine per mL, Bracco, Milan, Italy) was administered through a marginal auricular vein with an automated contrast injector pump (total volume 10 mL, flow rate 1.0 mL/s, maximum infusion pressure 100 psi). The localizer was placed 2 cm below the level of the knee articulation and a dynamic computed tomography protocol was executed with the following parameters: scan type cine, 120 KV, 60 mAs, rotation time 1 second, slice thickness 5 mm, table feed 15 mm, FOV small, and matrix 512. Four tissue sections, each 5 mm thick, were reconstructed with a soft tissue kernel algorithm every 200 ms during a total scanning time of 20 seconds, after a start delay time of 5 seconds.
Images were further analyzed and postprocessed with the Analyze PC7 software (Analyze Direct, Inc., Overland Park, KS). A standard ROI (1 mm 2 ) was drawn in the center of the saphenous artery and the vessel enhancement in Hounsfield Units (HU) was calculated in every reconstructed image. Same areas ROIs were used in all cases for reasons of standardization. Hence, time-resolved attenuation curves of the vessel enhancement, which is representative of blood flow within the vessel, were calculated and plotted. Peak enhancement values of the intra-arterial space in Hounsfield units and the required time period for the signal to reach the peak value (time-to-peak) were recorded. In addition, tissue perfusion analysis was performed with the semiquantitative slope methodology, which focuses in the first-pass arterial phase and avoids re-circulation contamination. 23, 24 Briefly, tissue perfusion can be calculated as the maximum slope F of the contrast enhancement curve divided by the maximum arterial enhancement V:
Cross-sectional CT and magnetic resonance (MR) imaging. As an adjunct to perfusion imaging, routine contrast-enhanced cross-sectional imaging of the rabbit hindlimbs was performed with a second infusion of iodinated contrast. Scans extended from the bifurcation of the abdominal aorta to the toes and the acquisition protocol parameters were: scan type helical, 120 KV, 440 mAs, rotation time 1 second, pitch 0.562, slice thickness 0.625 mm, FOV small, and matrix 512. Data were analyzed and both routine axial images and reformatted multiplanar and volume-rendered images were viewed in order to assess the morphological architecture of the newly-developed collateral networks, as previously reported. 26 In order to further investigate tissue morphology and signal intensity in the medial thigh ischemic regions, where the angiogenic factors had been injected, subjects underwent in vivo gadolinium-enhanced MR imaging in a clinical 1.5 Tesla MRI system (Siemens Magnetom 1.5T Vision, Siemens Healthcare, Erlangen, Germany). MRI parameters were as follows: maximum gradient strength 25 mTm-1, rise time 200 s, and matrix 512 ϫ 512. Fat-saturation T1-weighted and T2-weighted sequences were acquired before (TE ϭ 20 ms, TR ϭ 860 ms) and after intravenous administration of gadolinium (TE ϭ 54 ms, TR ϭ 860 ms) with a scan delay of 10 seconds and axial, sagittal, and coronal sections were reconstructed and evaluated.
Histopathologic analysis. Hindlimbs of euthanized rabbits were dissected and muscle tissue specimens were harvested and fixed in formalin. Histopathologic analysis of the adductor muscle in the medial thigh was performed. Specimens were paraffin embedded and cut into 5 m slices. Anti-CD31 immunostaining was performed for the identification of endothelial cells and capillaries. Additional immunostaining for specific cell markers was also performed as indicated. Histologic analyses were performed in a blinded fashion. The number of arterioles in the entire sections were manually counted under optical microscopy (magnification ϫ20) and recorded with a digital camera.
Statistical analysis. Discrete variables were expressed as counts and percentages, while continuous variables were given as mean Ϯ standard error (SE). The unpaired Student t test was used for testing the significance of difference of variables that passed the normality test. Mann-Whitney test was used for qualitative variables and for continuous variables that did not pass the normality test. Analysis if variance (ANOVA) test was employed for group comparisons and the Tukey multiple comparison post-test was applied in case of statistically significant differences. The threshold of statistical significance was set at 5% (P Ͻ .05). (Graphpad Prism 5.0; Graphpad, San Diego, Calif).
RESULTS
Thrombin stimulates arteriogenesis in the rabbit ischemia model. Quantification of newly developed collateral vessels was performed DSA, which is considered the 
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most appropriate methodology for in vivo imaging of the microvessel networks. 19 Focusing in particular on the measurement of the arteriogenic outcome, we have segmented and quantified the large collaterals arteries (d Ͼ 500 m). As expected in all animals, hindlimb ischemia was generally followed by a considerable physiologic increase in muscular capillarity (Fig 2, A and B) . New collaterals originated from the internal iliac artery (Fig 2, B, number 2) were developed to bypass the femoral artery excision and protect the ischemic tissue from injury. This native arteriogenic response was profoundly augmented by thrombin (Fig 2, B, right  hindlimb) . Notably, in the representative DSA image of Fig  2, B the distal right saphenous artery (number 5) was readily visualized compared with the control left hindlimb, which is likely the result of the marked collateralization along the right medial thigh and the quicker distal blood flow circulation. The application of thrombin exhibited a dosedependent trend of arteriogenic augmentation with a statistically significant increase of 30.2% Ϯ 7.4% compared with the control hindlimb in the 5000 IU-thrombin group (P Ͻ .01, Fig 2, C) . The choice of thrombin concentration range (500 to 5000 IU) was based on its mean in vitro effective doses multiplied by one thousand. Our aim was to evaluate the effect of thrombin in reasonable dose range from a clinical viewpoint. In this context, we quantified and compared the effect of VEGF and bFGF with that of thrombin. At doses ranging from 1 to 10 g, VEGF and bFGF were unable to stimulate arteriogenesis in our rabbit hindlimb ischemia model (Fig 2, C) . A numerical increase of 15.0% Ϯ 10.4% was detected in the high dose group of bFGF (10 g), which, however, was not statistically significant. Although the intramuscular application of thrombin (5000 IU) influenced the arteriogenic response of treated hindlimbs, the endogenous response of the contralateral control hindlimbs was not observed to be affected. As shown in Fig 3, A and B , the mean total collateral vessel length and area of all (n ϭ 66) control hindlimbs were comparable and the variation limited, indicating a local effect of thrombin within the treated hindlimbs. However, when thrombin was administrated (intramuscularly) in a concentration as high as 15,000 IU, an increased arteriogenic response was measured not only in the 15,000 IU thrombin-treated limbs, but also in the contralateral control hindlimbs of the 15,000 IU-thrombin group (15,000 IU controls), where only normal saline had been injected. Calculation of total collateral vessel length and area demonstrated that injection of 15,000 IU of thrombin evoked a pronounced arteriogenic outcome in both treated and control limbs of the specific group (10,879 Ϯ 556 and 10,384 Ϯ 318 total area pixels, respectively, compared with 5882 Ϯ 230 of ischemic internal control limbs; P Ͻ .001), which was equivalent to the normal femoral arterial networks of nonoperated animals (10,028 Ϯ 670) that were included as a baseline external control group (Fig 3, A and B) . In addition, taking into consideration Hagen-Poiseuille's law for laminar flow conditions, which states that blood flow within one vessel increases according to the fourth power of the vessel diameter, we calculated the mean collateral diameter (defined as area/length) as a surrogate indicator of blood hemodynamics across the newly developed collateral networks. 16 Interestingly, in both treated and control hindlimbs of the high-dose 15,000 IU-thrombin group, a slight but statistically significant increase of mean collateral diameter was detected (2.75 Ϯ 002 and 2.77 Ϯ 003 pixels, respectively) in comparison to control ischemic and other growth factors groups, which exceeded also the mean arterial diameter of nonoperated normal subjects (2.66 Ϯ 002 pixels; P Ͻ .01, Fig 3, C) . Theoretically, even a small change in collateral vessel diameter may reflect high changes in blood conductance properties. In addition, three-dimensional and multiplanar reformatted images of cross-sectional contrast-enhanced CT visualized two distinct growth patterns of collateral networks: bridging collaterals interconnecting proximal and distal native arteries and branching arteriogenesis, which are in agreement with similar observations in rodent ischemia studies. 26 Specifically, new collateral vessels originated from the internal iliac artery and gave off multiple helical branches that connected distally to the saphenous artery close to the knee articulation (Fig 3, D) .
Consistent with the angiographic analysis, histopathologic analysis and CD-31 immunolocalization revealed significantly more arterioles present in the adductor muscle of thrombin-treated limbs (Fig 4, A) . The arteriolar count per optical field was more than double in the 5000 IU-thrombin hindlimbs compared with the control ones (P Ͻ .01), while in bFGF-or VEGF-treated himdlimbs no significant differences were counted (Fig 4, B) . In 15,000 IU-thrombin hindlimbs, as well as in the contralateral control limbs, the number of arterioles was significantly increased compared with ischemic control hindlimbs (P Ͻ .001) and was similar with that observed in 5000 IU-thrombin hindlimbs (Fig 4,  B) . However, further histologic examination of these muscle specimens revealed abundant proliferation and infiltration of nonspecific cells. Immunoreactions for characterization of these cells showed positive staining for PGM1 and PK1, which are fibroblast-specific immunomarkers, and positive for Sm-Actin, Vimentin, and S-100, which identify differentiating monocyte cells of mesenchymal origin (Fig  4, C) . These observations indicate the development of strong inflammation reaction in the site of 15,000 IUthrombin administration. Similar inflammatory response was not observed in the contralateral 15,000 IU-control limbs, neither in the 5000 IU-thrombin groups (data not shown). In line with these findings, contrast-enhanced CT and MR imaging showed profoundly higher enhancement and signal intensity only in the muscle tissues injected with 15,000 IU thrombin (Fig 5) , which is in accordance with a pronounced stimulation of soft tissue angiogenesis and inflammation on a microscopic level.
Thrombin improves hemodynamic recovery of distal ischemic tissue. The goal of therapeutic angiogenesis is not only to enhance ischemia-driven arteriogenesis but also to achieve hemodynamic recovery of blood flow to the distal ischemic tissue. Previous investigations have shown that angiographic collateral grading does not necessarily correlate positively with blood flow and tissue perfusion as assessed by microsphere techniques. 27 Dynamic CT and calculation of time-resolved vessel enhancement curves provide direct in vivo functional indicators of blood flow distal to the excised femoral artery. 23, 24 The evaluation of the hemodynamic functionality of thrombin-induced newly formed proximal collaterals was performed in a region distal to the original area of surgery and injection (Fig  2, A, white box) . As shown in Fig 6, A, dynamic CT of the saphenous artery showed a higher opacification of the right saphenous artery (right limb; 5000 IU thrombin) compared to the left one (internal control limb). The mean absolute value of peak enhancement, which represents blood-contrast concentration and is proportional to the arterial blood flow, showed a 100.9% Ϯ 40.9% increase (P Ͻ .05) in the hindlimbs that had received 5000 IU of thrombin in comparison to the contralateral control hindlimbs (Fig 6, B, left panel) . An increase of almost 50% was also observed in the high-dose (10 g) groups of VEGF and bFGF (Fig 6, B, left panel) . However, neither of these differences proved to be statistically significant. In addition, the mean time-to-peak enhancement was measured to be shorter for both thrombin (5000 IU) and bFGF (10 g) groups, indicating a quicker blood flow circulation (Fig 6,  B, right panel) . However, only for the thrombin group was this difference statistically significant (P Ͻ .05). The timeresolved plots of saphenous artery enhancement portray further the differences observed in the dynamics of blood circulation between limbs that were treated with different growth factors (Fig 6, C) . Interestingly, attenuation curves of thrombin treated limbs exhibited delayed but eminently higher enhancement than normal limbs, which likely reflects the more time-consuming circulation of higher blood volume through the more extensive collateralization stimulated by thrombin. These observations provide evidence that blood circulation through the newly developed collateral networks is more delayed compared to normal femoral arteries regardless of the growth factor applied and its arteriogenic outcome.
In line with the quantitative angiographic data, increased higher saphenous artery enhancement was documented both in the treated and control hindlimbs of the 15,000 IU-thrombin-treated animals (data not shown). Again, the absolute value of peak enhancement expressed in Hounsfield units, showed a 70% to 80% increase in the ischemic limbs injected with 15,000 IU of thrombin, as well as in the 15,000 IU control hindlimbs compared with normal subjects (Fig 6, D) , while the time-to-peak intervals were significantly delayed (P Ͻ .001, Fig 6, E) , suggesting that circulation dynamics are delayed due to the longer and tortuous collateral routes that blood has to travel in order to bypass the occluded native artery.
To further elucidate overall collateral blood conductance, we applied the slope method score, which is a semiquantitative surrogate endpoint of distal tissue blood perfusion. 24 Analysis of the dynamic CT data with the slope method showed a significant decrease of limb perfusion in the case of the ischemic control (5.0 Ϯ 0.3) and both VEGF (4.8 Ϯ 0.2) and bFGF (4.5 Ϯ 0.2) 10 g groups (P Ͻ .01, Fig 6, F) . Remarkably, however, there was no significant inferiority of the 5000 IU (5.7 Ϯ 0.3) and 15,000 IU (5.4 Ϯ 0.6) thrombin-treated limbs vs the score of normal rabbits (6.5 Ϯ 0.3; Fig 6, F) , suggesting a trend towards hemodynamic recovery and normalization of distal limb perfusion. Of interest, the same normalization of perfusion score was noted in the control limbs of the 15,000 IU thrombin group (5.6 Ϯ 0.4), which is in line with the increased arteriogenic outcome documented angiographically, pointing to a considerable systemic effect of thrombin in the reperfusion of the contralateral control ischemic limbs. Almost all study subjects exhibited extensive hair loss and ischemic ulcers along the tibia and the feet, most of which demonstrated improved or complete Immunoreactions of these cells were positive for PGM1 and PK1 (fibroblast-specific immunomarkers) and also positive for Sm-Actin, Vimentin, and S100 (relating to differentiating monocyte cells of mesenchymal origin, data not shown).
wound healing in the 5000 IU and 15,000 IU groups. However, no significant differences in comparison to groups with other growth factors or ischemic control limbs were noted (data not shown).
DISCUSSION
In this study, using a rabbit hindlimb ischemic model, we have shown that a single intramuscular injection of thrombin can enhance the angiogenic response to ischemia with a significant increase of regional collateralization and enhanced distal blood flow circulation. Based on the increased collateral area and length and the improved indices of tissue blood perfusion, thrombin treatment resulted in both angiographically and functionally better vasculature. Our findings further extend previous reports indicating that thrombin functions as a potent proangiogenic molecule. For instance, the ability of thrombin to stimulate the formation of vessels has been evidenced in the chick chorioallantoic membrane (CAM) system 7 and the matrigel in vivo model. 28 Furthermore, Dimitropoulou et al 29 have shown that thrombin significantly increased not only the number of vessel in CAM but also their diameters and lengths.
The principal goal of therapeutic angiogenesis is to develop collateral vessels that can restore sufficient blood flow in ischemic tissue. 30 Past studies for therapeutic angiogenesis sought to improve tissue perfusion through the delivery of angiogenic factors and cytokines such as bFGF, VEGF, or platelet-derived growth factor BB (PDGF-BB). However, single administration of these factors was found to be insufficient to establish stable vascular networks. Even if a single growth factor can initiate angiogenesis, it is becoming increasingly apparent that other cooperating factors and receptor-mediating mechanisms are required at later stages for the development of mature vascular networks. 31 Therefore, several reports have suggested the impact of combination of growth factors for therapeutic angiogenesis. For instance, the combination of bFGF and PDGF-BB synergistically induced vascular networks that remained stable for more than a year, even after the angiogenic factors were depleted. 32 In this regard, thrombin through its multiplicity of effects on angiogenesis, survival, Intermediate image after contrast infusion and arrival of contrast shows peak enhancement of the arteries. The bright enhancement within the arteries corresponds to the circulating blood volume. Bottom final image after digital subtraction of the above. B, Perfusion analysis of dynamic-CT study. Peak vessel enhancement (left panel) and the corresponding time-to-peak intervals (right panel) were calculated in the regions of saphenous arteries 20 days after single intramuscular administration of the indicated doses of VEGF or bFGF or thrombin. Results expressed as mean percentage change in comparison to internal control hindlimbs of each study group Ϯ SE. Each study group included seven to eight rabbits. *P Ͻ .05. C, Average time-resolved curves of saphenous artery enhancement were calculated in normal nonoperated hindlimbs (normal, n ϭ 6) or total control ischemic hindlimbs (control limbs, n ϭ 66) or hindlimbs treated with indicated doses of thrombin (n ϭ 7) or VEGF (n ϭ 8) or bFGF (n ϭ 8) or contralateral control hindlimbs of the 15,000 IU-thrombin treated limbs (15,000 IU controls, n ϭ 8). Results expressed as mean Hounsfield Units Ϯ SE. D and E, Dynamic CT perfusion analysis of 15,000 IU-thrombin treated rabbits. Peak vessel enhancement (D) and the corresponding time-to-peak enhancement (E) were calculated in the regions of saphenous arteries 20 days after single intramuscular administration of 15,000 IU thrombin. Results expressed as mean Hounsfield Units Ϯ SE (left panel) or as mean seconds Ϯ SE (right panel). ***P Ͻ .001. F, Semiquantitative perfusion score calculated with the slope method. 24 *P Ͻ .05.
interaction with other growth factors, and many cell types, may have the unique ability to orchestrate the requirements for the development of mature blood vessels. Although a long-term study of thrombin-induced neovascularization has not yet been accomplished, the high vessel maturity observed here might be a promising sign for long duration of their functionality. The mechanism underlying the arteriogenic effect induced by thrombin may be complex. A possible physiologic role of PAR1 in the reparative processes that result in tissue recovery is under investigation determining the protein and mRNA levels in ischemic adductor muscles and examining the effect of specific exogenous PAR1 activators. However, several aspects can be considered by previous studies. It is now recognized that thrombin is able to influence angiogenesis through both coagulation-dependent and coagulationindependent mechanisms. The coagulation-dependent pathways involve platelet activation and fibrin formation. Vessel wall injury or thrombus formation stimulates platelet to adhere to subendothelial matrix and to undergo activation by thrombin, leading to aggregation and degranulation. It should be emphasized that platelet ␣-granules are the source of a plethora of proangiogenic factors, including VEGF, bFGF, and PDGF-BB, 33, 34 and the absence of platelets inhibits the early stages of angiogenesis and contributes to the formation of decreased number of new vessels in vivo. 35, 36 In addition, fibrin networks, generated by thrombin in the local microenvironment of wound healing, inflammation, or malignant tumor growth, exert a supportive role for endothelial cell adhesion, survival, and angiogenesis. 37, 38 Fibrin also provides storage of proangiogenic growth factors, such as bFGF, and VEGF as well as thrombin itself, which are protected from proteolytic degradation and released by proteolytic enzymes, generated during invasion by endothelial cells. These reports are in line and explain the observations by other investigators, who have shown that the use of anticoagulant drugs after induction of tissue ischemia hampered spontaneous arteriogenic response in a rodent hindlimb ischemia model. 39 Accordingly, intramuscular injection of fibrin matrices promoted arteriogenesis in a rabbit hindlimb ischemia model. 40 On the other hand, many cellular actions of thrombin are regulated by mechanisms apart from its role in coagulation cascade. Thrombin is clearly accepted as the principal physiologic regulator of PAR1 and PAR4, 41 particularly in terms of targeting the cardiovascular system and inflammation, which is an early key process for ischemia-induced angiogenesis and arteriogenesis. 42 In this regard, many studies showed that thrombin and its receptors exist not only in the vascular wall and cells but also in immuneprivileged tissues and cells, which play important proinflammatory roles. Indeed, PAR1 expression has been found on many immune cells, including macrophages, monocytes, lymphocytes, and mast cells, and PAR4 appears to play a key role in thrombin-regulated leukocyte rolling and adherence. 43 Consequently, amassed data have documented the ability of thrombin to trigger many of the responses associated with inflammation, including endothelial cell activation (P-selectin display, increased adhesion of leukocytes and platelets), along with increased vascular permeability, mast cell degranulation, increased adhesion of neutrophils to the endothelium, platelet aggregation and chemotaxis of neutrophils, and the induction of cytokine release from epithelial and vascular smooth muscle and endothelial cells. Furthermore, thrombin acting through PAR1 has been shown to play an essential role in the generation of monocyte chemoattractant protein, which is a key molecule for the recruitment of monocytes and macrophages. 44 The important role of thrombin in initiating inflammatory responses provides a plausible explanation for the profound inflammatory reactions observed in those limbs receiving the highest dose (15,000 IU) of thrombin. At concentrations of thrombin up to 5000 IU, we found no evidence of focal inflammation, which may due to the fact that the inflammation reactions induced by thrombin were not that significant to cause a marked change in histology. However, it is likely that high concentrations of thrombin may mount a more robust reparative response by amplifying proinflammatory mechanisms implicated in angiogenesis.
There are several limitations in our study. First, we investigated arteriogenesis in the specific time-point of the 40th postsurgical day, 20 days after injection of thrombin. Although many investigators have followed this protocol, it is likely that the long 20-day postsurgery period masks part of the arteriogenic effect of thrombin. On the other hand, therapeutic angiogenesis in ischemia will be effective only if stable arteries can be developed. Taking into consideration that new collateral vessels require up to 20 days following the ischemic insult to fully develop, it is possible that repeated multiple injections of smaller doses or sustained release of thrombin from biodegradable systems would be better than bolus injection of high doses. Nonetheless, additional experiments have been designed to further investigate the time-dependence and dose-fractionation of thrombin-induced functional arteriogenesis. Second, the inability of VEGF and bFGF to stimulate arteriogenesis was likely due to the relative low doses used in our model. However, the aim of our comparative experiments was to evaluate the effect of thrombin, bFGF, and VEGF in reasonable dose ranges from a clinical viewpoint. As mentioned before, the range of concentrations used was based on their mean in vitro effective doses multiplied by one thousand. Third, we did not perform blood biochemistry tests to detect systemic circulation of thrombin or any alterations in blood coagulation parameters; neither did we evaluate the subjects for any ectopic thrombin activity like formation of venous clot or emboli. Although systemic VEGF and bFGF levels can be measured using elaborate high-affinity antagonist antibody assays, plasma thrombin is rapidly deactivated and can only be assayed indirectly from the levels of circulating fibrinopeptide A. 45 Such tests may be important since injection of 15,000 IU of thrombin exerted a pronounced arteriogenic effect also in the contralateral control limbs, which implies that there are sys-temic effects at these high-dose levels. Under those circumstances, a fractionated protocol of thrombin injection may readily achieve enhanced collateral augmentation whilst avoiding any potential toxicity or adverse effects from increased plasma levels.
CONCLUSION
The present study provides the first evidence of an arteriogenic role for thrombin. Thrombin improved limb ischemia in rabbits by promoting collateral vessel development and recovery of ischemic tissue perfusion. This is an exciting prospect and presents a challenge to both clinicians and basic scientists for understanding the role of thrombin in peripheral arterial disease. 
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